Limiting Sales Rep Access to Physicians: Do the Benefits Outweigh the Risks?
This article documents the concerns about the risks of drug sales reps as well as the benefits to physicians.
The Alternate Reality of Pharma CEOs: Their Views Regarding Drug Prices, Innovation, Taxes &...
Drug industry CEOs are busy talking publicly about drug prices, taxes, innovations, and other issues that need defending. Their arguments are highlighted in this article.
Pharma and Patient Advocacy Groups: Patient Centricity Finally Pays Off for Both
The big patient-centricity payoff for pharma is its relationship with patient advocacy groups that are recruited to lobby Congress, local governments and the FDA.
PinUp: Silicon Valley Health Venture Woes and Pharma Ups Its Influence in Washington
Welcome to the April 28, 2017, issue of Pharma Industry News Update (aka PinUp). The pharma industry lags other industries in its investment in digital technology. Silicon valley startups rush in to fill the void but have trouble raising funds due to hype and deception.
PinUp: The Internet of Things and the Impact on Outcomes and Adherence
Welcome to the April 25, 2017, issue of Pharma Industry News Update (aka PinUp). The drug industry should focus on using Internet of Things technology to improve health outcomes. Better adherence and profits will then follow.
PinUp: The Internet of Things and the Impact on Outcomes and Adherence
Welcome to the April 25, 2017, issue of Pharma Industry News Update (aka PinUp). The drug industry should focus on using Internet of Things technology to improve health outcomes. Better adherence and profits will then follow.
March for Science, Why I March
John (PharmaGuy) Mack
speaking at the March for Science in Doylestown, PA.
My name is John Mack and I
live in Newtown.
On Twitter I am known as
PharmaGuy...
PinUp: Go Boldly & March for Science, Why I March
Welcome to the April 21, 2017, issue of Pharma Industry News Update (aka PinUp). This issue is devoted to the March for Science.
Speedy Drug Approval Versus Safe Drugs: Can We Have Both?
More user fees paid to the FDA by the drug industry and the push for less rigorous scientific proof in clinical trials may lead...
PinUp: The Impact of FDA User Fees & Less Rigorous Scientific Proof on Drug...
Welcome to the April 18, 2017, issue of Pharma Industry News Update (aka PinUp). More user fees paid to the FDA by the drug industry and the push for less rigorous scientific proof in clinical trials may lead to faster drug approvals, but also more deaths due to side effects. Where’s the balance between speed and safety?
